{"analyses":[{"ciLowerLimit":"0.48","ciPctValue":"95","ciUpperLimit":"0.70","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.58","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"73.82","upperLimit":"80.15","value":"76.98"},{"groupId":"OG001","lowerLimit":"85.15","upperLimit":"90.03","value":"87.59"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"743"},{"groupId":"OG001","value":"743"}],"units":"Participants"}],"description":"DFS was defined as the time between randomization and the date of the first occurrence of an IDFS event including SPNBC event or contralateral or ipsilateral ductal carcinoma in situ (DCIS). IDFS event was defined as outlined in the description for IDFS rate OM number 1. 3-year DFS rate in the ITT population was estimated using KM method, and the percentage of participants who were event-free 3 years after randomization was estimated.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received trastuzumab, 6 mg/kg, IV, Q3W, as a maintenance dose for 14 cycles (1 cycle = 21 days) or until disease recurrence or unacceptable toxicity which ever occurs first.","id":"OG000","title":"Trastuzumab"},{"description":"Participants received trastuzumab emtansine, 3.6 mg/kg, IV, Q3W for 14 cycles (1 cycle = 21 days) or until disease recurrence or unacceptable toxicity which ever occurs first.","id":"OG001","title":"Trastuzumab Emtansine"}],"paramType":"NUMBER","populationDescription":"ITT population included all participants who were randomized to the study regardless of whether they received any study treatment.","reportingStatus":"POSTED","timeFrame":"At Year 3","title":"Disease-free Survival (DFS) Rate at 3 Years","type":"SECONDARY","unitOfMeasure":"percentage of participants"}